These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12821362)

  • 1. The role of PET scanning in the detection of recurrent cervical cancer.
    Havrilesky LJ; Wong TZ; Secord AA; Berchuck A; Clarke-Pearson DL; Jones EL
    Gynecol Oncol; 2003 Jul; 90(1):186-90. PubMed ID: 12821362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
    Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women.
    Unger JB; Ivy JJ; Connor P; Charrier A; Ramaswamy MR; Ampil FL; Monsour RP
    Gynecol Oncol; 2004 Jul; 94(1):212-6. PubMed ID: 15262145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
    Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
    Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of FDG PET in patients with cervical cancer.
    Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
    J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
    Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
    J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
    J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report.
    Chang WC; Hung YC; Lin CC; Shen YY; Kao CH
    Cancer Invest; 2004; 22(2):180-4. PubMed ID: 15199599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
    Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.
    Brooks RA; Rader JS; Dehdashti F; Mutch DG; Powell MA; Thaker PH; Siegel BA; Grigsby PW
    Gynecol Oncol; 2009 Jan; 112(1):104-9. PubMed ID: 18929403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA.
    Sarikaya I; Bloomston M; Povoski SP; Zhang J; Hall NC; Knopp MV; Martin EW
    World J Surg Oncol; 2007 Jun; 5():64. PubMed ID: 17555577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
    Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
    Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.